Literature DB >> 23031786

Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer.

Hong Lin1, Jian-Fei Huang, Jin-Rong Qiu, Hui-Lin Zhang, Xiao-Jun Tang, Hu Li, Chang-Jun Wang, Zhong-Can Wang, Zhen-Qing Feng, Jin Zhu.   

Abstract

The tumor-associated calcium signal transducer 2 (TACSTD2) gene has been reported to be highly expressed in many types of human epithelial cancers, and is associated with tumor metastasis and poor prognosis. The aims of the present investigation were to analyze the TACSTD2 and Cyclin D1 expression at the mRNA and protein levels and to assess its prognostic significance in invasive ductal breast cancer (IDC). The expressions of TACSTD2 and Cyclin D1 in IDC tissues were consistently higher than those in the tumor-adjacent non-malignant tissues by a one-step real-time polymerase chain reaction and immunohistochemistry (P<0.001 and P=0.023, respectively). The statistical analysis of clinicopathologic characteristics and immunohistochemistry by the χ(2) test showed that the high expression of TACSTD2 in IDC was correlated to histological grade (P=0.023), P53 status (P=0.042), Cyclin D1 status (P<0.001), lymph node metastasis (P<0.001), distant metastasis (P=0.004) and TNM staging (P<0.001). Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of IDC. These analyses also showed that a high TACSTD2 expression (P=0.003), a high Cyclin D1 expression (P=0.041), and lymph node metastasis (P=0.006) were independent prognosis factors. Collectively, our studies demonstrated that the high expression of TACSTD2 correlates with a poor prognosis in IDC.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23031786     DOI: 10.1016/j.yexmp.2012.08.004

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  32 in total

1.  Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Jennifer R Diamond; Rebecca L Moroose; Steven J Isakoff; Alexander N Starodub; Nikita C Shah; Joyce O'Shaughnessy; Kevin Kalinsky; Michael Guarino; Vandana Abramson; Dejan Juric; Sara M Tolaney; Jordan Berlin; Wells A Messersmith; Allyson J Ocean; William A Wegener; Pius Maliakal; Robert M Sharkey; Serengulam V Govindan; David M Goldenberg; Linda T Vahdat
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

2.  TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation.

Authors:  J Kang; W Kim; S Lee; D Kwon; J Chun; B Son; E Kim; J-M Lee; H Youn; B Youn
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

3.  Scinderin-knockdown inhibits proliferation and promotes apoptosis in human breast carcinoma cells.

Authors:  Wenjing Jian; Xiaoli Zhang; Jiguo Wang; Yunlong Liu; Chuting Hu; Xianming Wang; Renbin Liu
Journal:  Oncol Lett       Date:  2018-06-21       Impact factor: 2.967

Review 4.  The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.

Authors:  S Michaleas; A Moreno Oliver; J Mueller-Berghaus; S B Sarac; M E van der Elst; S Müller-Egert; H Zander; H Enzmann; F Pignatti
Journal:  ESMO Open       Date:  2022-05-25

Review 5.  Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Authors:  Aiko Nagayama; Leif W Ellisen; Bruce Chabner; Aditya Bardia
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

6.  Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.

Authors:  Ning Xu; Zhihong Zhang; Jin Zhu; Lu Xu; Yuhua Li; Lei Duan; Yuan Mao; Hongxia Li
Journal:  Int J Exp Pathol       Date:  2016-04-29       Impact factor: 1.925

Review 7.  Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.

Authors:  K M Fenn; K Kalinsky
Journal:  Drugs Today (Barc)       Date:  2019-09       Impact factor: 2.245

8.  Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type.

Authors:  Renjie Chen; Meiping Lu; Jun Wang; Dawei Zhang; Hong Lin; Huijun Zhu; Weiming Zhang; Lin Xiong; Jun Ma; Yuan Mao; Jin Zhu; Jiaren Xu
Journal:  Virchows Arch       Date:  2013-08-25       Impact factor: 4.064

Review 9.  Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive.

Authors:  Dey Nandini; Aske Jennifer
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-12

10.  High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer.

Authors:  Abdul K Siraj; Sandeep Kumar Parvathareddy; Padmanaban Annaiyappanaidu; Saeeda O Ahmed; Nabil Siraj; Asma Tulbah; Fouad Al-Dayel; Dahish Ajarim; Khawla S Al-Kuraya
Journal:  Onco Targets Ther       Date:  2021-05-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.